Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 2, 1, 7, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Genentech Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Novartis AG
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Therapure Biopharma Inc
Unicyte AG
Versantis AG
Vital Therapies Inc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Failure (Hepatic Insufficiency) - Overview
Liver Failure (Hepatic Insufficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Genentech Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Novartis AG
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Therapure Biopharma Inc
Unicyte AG
Versantis AG
Vital Therapies Inc
Liver Failure (Hepatic Insufficiency) - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-1220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ImmuneSafe - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipatasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silibinin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP3A4 for Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Failure (Hepatic Insufficiency) - Dormant Projects
Liver Failure (Hepatic Insufficiency) - Discontinued Products
Liver Failure (Hepatic Insufficiency) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference
Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group
Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
Jun 08, 2017: First patient included in PledPharma's clinical trial with Aladote
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure
May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure
Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid
Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01
Dec 31, 2015: Positive in vivo efficacy and safety results pave the way for the regulatory preclinical studies
Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Novartis AG, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Therapure Biopharma Inc, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Versantis AG, H2 2017
Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H2 2017
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2017
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2017
List of Figures
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
